Can trans resveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?

doi: 10.7417/CT.2017.2013

  • A. Malvasi Department of Obstetric & Gynecology, Santa Maria Hospital, GVM Care & Research, Bari, Italy; Laboratory of Human Anatomy, Department of Applied Mathematics, Moscow Institute of Physics and Technology (State University), Moscow Region, Russia
  • I. Kosmas Department of Obstetrics and Gynecology, University of Ioannina, Medical School, Greece; Laboratory of Human Anatomy, Department of Applied Mathematics, Moscow Institute of Physics and Technology (State University), Moscow Region, Russia
  • O.A. Mynbaev Laboratory of Human Anatomy, Moscow Institute of Physics and Technology (State University), Dolgoprudny, Moscow Region, Russia; Peoples’ Friendship University of Russia, Moscow, Russia; Moscow State University of Medicine and Dentistry, Moscow, Russia
  • R. Sparic School of Medicine, University of Belgrade, Belgrade, Serbia, Clinic for Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade, Serbia
  • S. Gustapane Department of Obstetric and Gynecology, Salus Hospital, Brindisi, Italy
  • M. Guido Laboratory of Hygiene, Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy
  • A. Tinelli Department of Obstetrics and Gynecology, Division of Experimental Endoscopic Surgery, Imaging, Technology and Minimally Invasive Therapy; Laboratory of Human Anatomy, Department of Applied Mathematics, Moscow Institute of Physics and Technology (State University), Moscow Region, Russia; Department of Obstetrics and Gynecology. Vito Fazzi Hospital, Lecce, Italy

Abstract

Objective
To investigate the effect of trans-resveratrol from Polygonum cuspidatum/magnesium hydroxide complex, trademark Revifast®, plus D-chiro-inositol (DCI) and Myo-inositol (MI) during spontaneous pregnancies in overweight patients in a pilot study.


Study design
A one-year, prospective, randomized, double-blinded, placebo-controlled single center clinical study was carried out on overweight pregnant women. 110 patients were randomized in 3 groups to receive: Revifast® with DCI/MI (group I), DCI/MI alone (group II) or control group (group III) for 30 and 60 days. The main outcomes were to explore the lipid profile (total cholesterol, LDL, HDL, TG) and glucose levels, after 30 and 60 days of therapy.


Results
No difference in systolic and diastolic parameters among 3 groups during study. All blood chemistry parameters improved compared to placebo at 30 days already, but significantly to 60 days, respect placebo. By comparing the two treatment groups, group I demonstrates significantly improved lipid and glucose parameters than group II, which are at 30 to 60 days of treatment.


Conclusion
The supplementation of Trans-resveratrol, Revifast® in addition to DCI/MI in overweight pregnant woman with an elevated fasting glucose improves glucose levels, Total Cholesterol, LDL and TG

Published
2017-07-13
How to Cite
MALVASI, A. et al. Can trans resveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?. La Clinica Terapeutica, [S.l.], v. 168, n. 4, p. e240 - e247, july 2017. ISSN 1972-6007. Available at: <http://www.clinicaterapeutica.it/ojs/index.php/ClinicaTerapeutica/article/view/50>. Date accessed: 14 nov. 2018.
Section
Clinical Trial